Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on tissue repair, announced strong interest and engagement from orthopedic surgeons, physicians, and cartilage repair specialists at the 8th International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, held Oct. 8-10 in Porto, Portugal. The discussions centered on GelrinC, the company’s CE Mark-approved, cell-free hydrogel implant designed to regenerate damaged knee cartilage through a single procedure lasting approximately 10 minutes.
In a Phase II study, GelrinC demonstrated approximately 100% greater improvement in overall Knee Injury and Osteoarthritis Outcome Score (KOOS) scores compared with historical microfracture controls at two years, with subsequent MRI analyses showing results consistent with durable, native-like cartilage regeneration. These data underscore the product’s potential to offer a less invasive, off-the-shelf solution for patients suffering from knee cartilage damage.
The strong surgeon interest at the ICRS Summit matters because it signals a critical step toward broader clinical adoption. Regentis is working to translate that interest into practice through its expanding European Centers of Excellence while advancing its ongoing U.S. Food and Drug Administration pivotal trial. If successful, GelrinC could address a significant unmet need: approximately 470,000 cartilage knee repair cases annually in the U.S., where no off-the-shelf treatment is currently available.
For investors, the news highlights Regentis’ progress in a market with substantial potential. The company’s Gelrin platform technology, based on synchronized, degradable hydrogel implants, is designed to regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
To view the full press release, visit https://ibn.fm/hcEu4. The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT.
The dissemination of this content was facilitated by InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, please visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
